Hodgkin’s Lymphoma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances by DelveInsight | Checkpoint Therapeutics, Mundipharma Research, Aurigene Discovery, Immunitas Therapeutics, AstraZeneca

Posted on
by

Hodgkin’s Lymphoma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances by DelveInsight | Checkpoint Therapeutics, Mundipharma Research, Aurigene Discovery, Immunitas Therapeutics, AstraZeneca
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hodgkin’s Lymphoma pipeline constitutes 15+ key companies continuously working towards developing 20+ Hodgkin’s Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hodgkin’s Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hodgkin’s Lymphoma Market.

 

The Hodgkin’s Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Hodgkin’s Lymphoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Hodgkin’s Lymphoma treatment therapies with a considerable amount of success over the years. 

  • Hodgkin’s Lymphoma companies working in the treatment market are Checkpoint Therapeutics, Inc., Mundipharma Research Ltd., Aurigene Discovery Technologies Ltd., Immunitas Therapeutics, AstraZeneca, Tessa Therapeutics, CStone Pharmaceuticals, Tesirine ADC Therapeutics, Angiocrine Bioscience, and others, are developing therapies for the Hodgkin’s Lymphoma treatment 

  • Emerging Hodgkin’s Lymphoma therapies in the different phases of clinical trials are- CK-301, Tinostamustine, AUR105, IMT-009, AZD7789, CD30.CAR-T, CS1001, Camidanlumab, AB-205, and others are expected to have a significant impact on the Hodgkin’s Lymphoma market in the coming years.   

  • In August 2023, Chimeric Therapeutics is now in Phase I of the clinical development of CHM-0201, a treatment for B-Cell Hodgkin Lymphoma. The phase transition success rate (PTSR) indication benchmark for Hodgkin lymphoma (B-cell Hodgkin lymphoma) medications in Phase I is 72%

  • In February 2022, A Phase 3 Double-Blind, Randomised, Placebo Controlled Study to Compare AB-205 Plus Standard of Care to Placebo Plus Standard of Care in Adults With Lymphoma Receiving High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE) was started by Angiocrine Bioscience

 

Hodgkin’s Lymphoma Overview

Hodgkin’s lymphoma, also known as Hodgkin lymphoma or Hodgkin disease, is a type of cancer that originates from white blood cells called lymphocytes. It is characterized by the presence of a specific type of abnormal cell called Reed-Sternberg cells in the lymph nodes. These abnormal cells are large, multinucleated cells that are typically derived from B lymphocytes (B cells).

 

Get a Free Sample PDF Report to know more about Hodgkin’s Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight

 

Emerging Hodgkin’s Lymphoma Drugs Under Different Phases of Clinical Development Include:

  • CK-301: Checkpoint Therapeutics, Inc.

  • Tinostamustine: Mundipharma Research Limited

  • AUR105: Aurigene Discovery Technologies Limited

  • IMT-009: Immunitas Therapeutics

  • AZD7789: AstraZeneca

  • CD30.CAR-T: Tessa Therapeutics

  • CS1001: CStone Pharmaceuticals

  • Camidanlumab: Tesirine ADC Therapeutics

  • AB-205: Angiocrine Bioscience

 

Hodgkin’s Lymphoma Route of Administration

Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Hodgkin’s Lymphoma Molecule Type

Hodgkin’s Lymphoma Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Hodgkin’s Lymphoma Pipeline Therapeutics Assessment

  • Hodgkin’s Lymphoma Assessment by Product Type

  • Hodgkin’s Lymphoma By Stage and Product Type

  • Hodgkin’s Lymphoma Assessment by Route of Administration

  • Hodgkin’s Lymphoma By Stage and Route of Administration

  • Hodgkin’s Lymphoma Assessment by Molecule Type

  • Hodgkin’s Lymphoma by Stage and Molecule Type

 

DelveInsight’s Hodgkin’s Lymphoma Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Hodgkin’s Lymphoma product details are provided in the report. Download the Hodgkin’s Lymphoma pipeline report to learn more about the emerging Hodgkin’s Lymphoma therapies

 

Some of the key companies in the Hodgkin’s Lymphoma Therapeutics Market include:

Key companies developing therapies for Hodgkin’s Lymphoma are – Actiza Pharmaceutical Private Limited, Alkem Laboratories, Amneal Pharmaceuticals, Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, LGM Pharma, Merck & Co. Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and others.

 

Hodgkin’s Lymphoma Pipeline Analysis:

The Hodgkin’s Lymphoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin’s Lymphoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin’s Lymphoma Treatment.

  • Hodgkin’s Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hodgkin’s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin’s Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Hodgkin’s Lymphoma drugs and therapies

 

Hodgkin’s Lymphoma Pipeline Market Drivers

  • Increase in prevalence of Hodgkin’s Lymphoma, increase in awareness about the disease are some of the important factors that are fueling the Hodgkin’s Lymphoma Market.

 

Hodgkin’s Lymphoma Pipeline Market Barriers      

  • However, side effects associated with the treatment, cost associated with the treatment and other factors are creating obstacles in the Hodgkin’s Lymphoma Market growth.

 

Scope of Hodgkin’s Lymphoma Pipeline Drug Insight    

  • Coverage: Global

  • Key Hodgkin’s Lymphoma Companies: Checkpoint Therapeutics, Inc., Mundipharma Research Ltd., Aurigene Discovery Technologies Ltd., Immunitas Therapeutics, AstraZeneca, Tessa Therapeutics, CStone Pharmaceuticals, Tesirine ADC Therapeutics, Angiocrine Bioscience, and others

  • Key Hodgkin’s Lymphoma Therapies: CK-301, Tinostamustine, AUR105, IMT-009, AZD7789, CD30.CAR-T, CS1001, Camidanlumab, AB-205, and others

  • Hodgkin’s Lymphoma Therapeutic Assessment: Hodgkin’s Lymphoma current marketed and Hodgkin’s Lymphoma emerging therapies

  • Hodgkin’s Lymphoma Market Dynamics: Hodgkin’s Lymphoma market drivers and Hodgkin’s Lymphoma market barriers 

 

Request for Sample PDF Report for Hodgkin’s Lymphoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Hodgkin’s Lymphoma Report Introduction

2. Hodgkin’s Lymphoma Executive Summary

3. Hodgkin’s Lymphoma Overview

4. Hodgkin’s Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Hodgkin’s Lymphoma Pipeline Therapeutics

6. Hodgkin’s Lymphoma Late Stage Products (Phase II/III)

7. Hodgkin’s Lymphoma Mid Stage Products (Phase II)

8. Hodgkin’s Lymphoma Early Stage Products (Phase I)

9. Hodgkin’s Lymphoma Preclinical Stage Products

10. Hodgkin’s Lymphoma Therapeutics Assessment

11. Hodgkin’s Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hodgkin’s Lymphoma Key Companies

14. Hodgkin’s Lymphoma Key Products

15. Hodgkin’s Lymphoma Unmet Needs

16 . Hodgkin’s Lymphoma Market Drivers and Barriers

17. Hodgkin’s Lymphoma Future Perspectives and Conclusion

18. Hodgkin’s Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services